Image Credit: Adobe Stock Images/Jordi.com

Ascensia Diabetes Care—a part of PHC Group—has signed a memorandum of understanding (MOU) to transfer the commercial operations for its branded Eversense Continuous Glucose Monitoring (CGM) systems to Eversense designer Senseonics Holdings, Inc.¹

Pending an official agreement, the parties are aiming to merge Eversense R&D, manufacturing, and commercial services with Senseonics starting Jan. 1 of next year.

Background: Ascensia and Senseonics partnership

Per its partnership with Senseonics, Ascensia obtained the global distribution rights for Eversense in 2020 and in October 2024, unveiled Eversense 365, a one-year CGM system, in the United States. The collective parties are referred to as PHC Group.

Why the transition matters

As Eversense continues its expansion, the CGM maker’s go-to-market strategy has diverged further from what is considered Ascensia’s traditional blood glucose monitoring business. PHC Group, Ascensia, and Senseonics feel that the consolidation of development, manufacturing, and distribution within Senseonics will allow for Eversense to scale more quickly and achieve its full potential sooner than under the existing setup.

Impact on partners, patients, and providers

There will be minimal interruptions for partners, patients, and providers; once the agreement is signed, a majority of the Eversense commercial team will be shifting over to Senseonics. Eversense’s commmercial operations will also be transferred to Senseonics.

"We are very proud to have worked with Senseonics on commercializing Eversense ,and we are committed to supporting Senseonics in establishing their own commercial operations and smoothly transitioning to them when we have a definitive agreement,” said Koichiro Sato, chief operating officer and chief strategy officer of PHC Group and CEO of Ascensia. “PHC Group remains invested in Senseonics and will continue to explore additional growth opportunities in the diabetes space."

Senseonics leadership emphasized the strategic importance of this transition, with president and CEO Tim Goodnow adding,"Eversense is truly differentiated from any other CGM system on the market, and we believe now is the time to bring manufacturing and commercialization together to allow Senseonics to grow and remain responsive to the future needs of people with diabetes. We truly appreciate the partnership and investment that PHC Group and Ascensia have made in Senseonics, and we look forward to welcoming the talented commercial team and continuing to build momentum for Eversense 365."

Recognition for Eversense 365

Eversense 365’s CGM System was also recently named the “Best New Technology Solution” for diabetes management in this year’s annual MedTech Breakthrough Awards Program.²

The program honors game-changing digital health and medical technology products and companies. The system is currently offered exclusively in the United States for adults with diabetes aged 18 and older, but Senseonics has submitted an application for CE Mark approval to bring Eversense 365 to the European market.

“We’re delighted that Eversense 365 has been named the Best New Technology Solution for Diabetes Management in the 2025 MedTech Breakthrough Awards program,” expressed Brian Hansen, Ascensia’s president of CGM. “The recognition is a testament to the technology’s standout innovation, as well as Ascensia’s unwavering commitment to improving the lives of people with diabetes through innovations in diabetes management technology. We’re proud of the unrivalled benefits Eversense 365 can deliver to people with diabetes as the world’s first and only one year CGM system. Our focus remains on bringing Eversense 365 to more people across the US, as well as expanding our offering into Europe.”

References

1. Ascensia Diabetes Care Signs MOU to Transfer Eversense CGM Distribution to Strategic Partner Senseonics. Gilead Sciences. September 4, 2025. Accessed September 5, 2025. https://www.ascensia.com/press/press-releases/press-release/?id=d7a85a04-156a-40e8-bb7d-5c22c5c78e77

2. Eversense 365 Recognized for Diabetes Management Innovation in 2025 MedTech Breakthrough Awards. Gilead Sciences. May 8, 2025. Accessed September 5, 2025. https://www.ascensia.com/press/press-releases/press-release/?id=db9345bc-6f2f-4111-a471-ea4984f052c2